Tandem Diabetes Care, Inc. $TNDM Position Raised by Intech Investment Management LLC

Intech Investment Management LLC raised its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 55.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 73,493 shares of the medical device company’s stock after purchasing an additional 26,150 shares during the quarter. Intech Investment Management LLC owned about 0.11% of Tandem Diabetes Care worth $892,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of TNDM. CoreCap Advisors LLC lifted its holdings in shares of Tandem Diabetes Care by 270.3% in the third quarter. CoreCap Advisors LLC now owns 4,751 shares of the medical device company’s stock valued at $58,000 after buying an additional 3,468 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Tandem Diabetes Care in the third quarter worth about $97,000. 180 Wealth Advisors LLC bought a new stake in Tandem Diabetes Care in the third quarter worth about $126,000. Praxis Investment Management Inc. acquired a new stake in Tandem Diabetes Care in the 3rd quarter valued at about $150,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Tandem Diabetes Care by 218.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,168 shares of the medical device company’s stock valued at $171,000 after acquiring an additional 6,290 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on TNDM. Robert W. Baird set a $30.00 target price on shares of Tandem Diabetes Care and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Royal Bank Of Canada reissued an “outperform” rating and set a $30.00 price objective on shares of Tandem Diabetes Care in a research note on Wednesday, December 17th. Canaccord Genuity Group set a $35.00 target price on Tandem Diabetes Care and gave the stock a “buy” rating in a research report on Wednesday, December 17th. UBS Group reaffirmed a “neutral” rating and set a $22.00 target price (up from $17.00) on shares of Tandem Diabetes Care in a report on Friday, February 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tandem Diabetes Care in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.11.

Tandem Diabetes Care Trading Down 6.6%

NASDAQ TNDM opened at $21.14 on Monday. The firm’s 50 day moving average price is $21.40 and its two-hundred day moving average price is $18.02. The company has a debt-to-equity ratio of 2.00, a quick ratio of 2.02 and a current ratio of 2.55. Tandem Diabetes Care, Inc. has a twelve month low of $9.98 and a twelve month high of $29.65. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -6.89 and a beta of 1.62.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Thursday, February 19th. The medical device company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.04. The business had revenue of $290.38 million for the quarter, compared to the consensus estimate of $277.14 million. Tandem Diabetes Care had a negative return on equity of 68.23% and a negative net margin of 20.17%.Tandem Diabetes Care’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.01 earnings per share. Equities analysts anticipate that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.